Immunitybio Inc (IBRX)

Jan 17, 2025, 2:05 PM EST - 11 hours ago

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 16, 2025, 2:25 PM EST - 1 day ago

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

Jan 15, 2025, 5:20 PM EST - 2 days ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Jan 15, 2025, 5:20 PM EST - 2 days ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Jan 6, 2025, 9:00 AM EST - 11 days ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Dec 16, 2024, 12:24 AM EST - 4 weeks ago

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

Dec 13, 2024, 2:40 PM EST - 5 weeks ago

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

Dec 12, 2024, 8:00 AM EST - 5 weeks ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Dec 11, 2024, 7:30 AM EST - 5 weeks ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Dec 10, 2024, 4:24 PM EST - 5 weeks ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Nov 21, 2024, 10:00 AM EST - 2 months ago

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

Nov 19, 2024, 9:00 AM EST - 2 months ago

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Nov 19, 2024, 8:00 AM EST - 2 months ago

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Nov 12, 2024, 7:15 AM EST - 2 months ago

ImmunityBio Reports Third-Quarter 2024 Financial Results

Oct 28, 2024, 7:53 AM EDT - 2 months ago

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025

Oct 25, 2024, 8:22 AM EDT - 3 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

SRRK

Oct 24, 2024, 9:00 AM EDT - 3 months ago

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Oct 23, 2024, 3:35 PM EDT - 3 months ago

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio

Oct 21, 2024, 9:00 AM EDT - 3 months ago

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Oct 7, 2024, 11:18 AM EDT - 3 months ago

ImmunityBio: Moving The Needle

Sep 21, 2024, 7:02 PM EDT - 4 months ago

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Sep 9, 2024, 8:30 AM EDT - 4 months ago

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

Aug 16, 2024, 7:57 AM EDT - 5 months ago

Top 3 Health Care Stocks That Are Set To Fly This Quarter

HAE PGNY

Aug 14, 2024, 2:13 PM EDT - 5 months ago

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Aug 12, 2024, 8:46 AM EDT - 5 months ago

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

Aug 6, 2024, 9:00 AM EDT - 5 months ago

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

Jul 25, 2024, 11:02 AM EDT - 6 months ago

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

Jun 25, 2024, 3:44 PM EDT - 7 months ago

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

Jun 20, 2024, 9:00 AM EDT - 7 months ago

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

Jun 7, 2024, 9:13 AM EDT - 8 months ago

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

Jun 6, 2024, 3:09 PM EDT - 8 months ago

ImmunityBio: Anktiva's Launch Demands A Reassessment

May 17, 2024, 9:00 AM EDT - 8 months ago

Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

May 7, 2024, 8:00 AM EDT - 9 months ago

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

May 2, 2024, 4:04 PM EDT - 9 months ago

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Apr 30, 2024, 8:00 AM EDT - 9 months ago

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

Apr 29, 2024, 11:26 AM EDT - 9 months ago

What's going on with the ImmunityBio (IBRX) stock price?

Apr 25, 2024, 12:03 AM EDT - 9 months ago

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Apr 23, 2024, 12:40 PM EDT - 9 months ago

ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications

Apr 23, 2024, 4:07 AM EDT - 9 months ago

Here's why ImmunityBio (IBRX) stock price surged and what next

Apr 22, 2024, 9:56 PM EDT - 9 months ago

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Apr 22, 2024, 6:38 PM EDT - 9 months ago

U.S. FDA approves ImmunityBio's bladder cancer therapy

Mar 6, 2024, 9:00 AM EST - 11 months ago

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

Mar 5, 2024, 9:00 AM EST - 11 months ago

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Feb 21, 2024, 9:00 AM EST - 11 months ago

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Feb 11, 2024, 2:41 AM EST - 1 year ago

ImmunityBio: Buy Low Now Vs. Buy High Later

Feb 5, 2024, 9:00 AM EST - 1 year ago

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Jan 2, 2024, 6:00 AM EST - 1 year ago

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Nov 16, 2023, 9:00 AM EST - 1 year ago

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference

Nov 7, 2023, 9:00 AM EST - 1 year ago

First Data for ImmunityBio's Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity